Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors.
증례연속
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: progressive liver metastases following immune checkpoint inhibitors (ICI) treatment
I · Intervention 중재 / 시술
DSM-TACE without discontinuation of systemic checkpoint inhibitor therapy from January 2023 to September 2024
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Cocnclusion. Incorporating locoregional therapies, such as DSM-TACE, in patients with liver metastases from cutaneous melanoma undergoing ICI treatment is feasible, safe, and effective in achieving local disease control, potentially extending PFS and OS.
[OBJECTIVES] To assess the safety and efficacy of performing degradable starch microspheres transarterial chemoembolization (DSM-TACE) in metastatic melanoma (MM) patients with progressive liver metas
APA
Auer TA, Schlaak M, et al. (2026). Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors.. Cardiovascular and interventional radiology, 49(3), 508-513. https://doi.org/10.1007/s00270-025-04218-0
MLA
Auer TA, et al.. "Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors.." Cardiovascular and interventional radiology, vol. 49, no. 3, 2026, pp. 508-513.
PMID
41145770 ↗
Abstract 한글 요약
[OBJECTIVES] To assess the safety and efficacy of performing degradable starch microspheres transarterial chemoembolization (DSM-TACE) in metastatic melanoma (MM) patients with progressive liver metastases following immune checkpoint inhibitors (ICI) treatment.
[MATERIAL AND METHODS] This case series evaluates 10 adult patients with MM who exhibited hepatic progression after an initial response to ICI therapy and underwent DSM-TACE without discontinuation of systemic checkpoint inhibitor therapy from January 2023 to September 2024. Tumor response was assessed using RECIST 1.1 criteria. The primary outcome measure of the study was the best overall response rate. Secondary outcome measures included local tumor control, progression-free survival, and overall survival. Adverse events were monitored and recorded.
[RESULTS] Ten melanoma patients (median age: 69.5 years; six females) who underwent DSM-TACE due to hepatic progression following an initial response to ICI therapy were included for safety analysis. Imaging data were unavailable for two patients, who were therefore excluded from further analyses. Best overall response rate was 87.5% (CR in two patients, PR in five patients, and SD in one patient). All treated lesions displayed sustained local tumor control throughout the follow-up. Six patients (75%) experienced the occurrence of new intra- or extrahepatic metastases. The median PFS was 8.5 months. Median OS was 12 months. Severe or life-threatening (grade 3-4) AEs associated with the combined treatment were reported in 40% (4/10-pseudoaneurysm at the puncture side, immune-related pancreatitis, anthracnosis, and colitis). Cocnclusion. Incorporating locoregional therapies, such as DSM-TACE, in patients with liver metastases from cutaneous melanoma undergoing ICI treatment is feasible, safe, and effective in achieving local disease control, potentially extending PFS and OS.
[MATERIAL AND METHODS] This case series evaluates 10 adult patients with MM who exhibited hepatic progression after an initial response to ICI therapy and underwent DSM-TACE without discontinuation of systemic checkpoint inhibitor therapy from January 2023 to September 2024. Tumor response was assessed using RECIST 1.1 criteria. The primary outcome measure of the study was the best overall response rate. Secondary outcome measures included local tumor control, progression-free survival, and overall survival. Adverse events were monitored and recorded.
[RESULTS] Ten melanoma patients (median age: 69.5 years; six females) who underwent DSM-TACE due to hepatic progression following an initial response to ICI therapy were included for safety analysis. Imaging data were unavailable for two patients, who were therefore excluded from further analyses. Best overall response rate was 87.5% (CR in two patients, PR in five patients, and SD in one patient). All treated lesions displayed sustained local tumor control throughout the follow-up. Six patients (75%) experienced the occurrence of new intra- or extrahepatic metastases. The median PFS was 8.5 months. Median OS was 12 months. Severe or life-threatening (grade 3-4) AEs associated with the combined treatment were reported in 40% (4/10-pseudoaneurysm at the puncture side, immune-related pancreatitis, anthracnosis, and colitis). Cocnclusion. Incorporating locoregional therapies, such as DSM-TACE, in patients with liver metastases from cutaneous melanoma undergoing ICI treatment is feasible, safe, and effective in achieving local disease control, potentially extending PFS and OS.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.